

## EDITORIAL ADVISORY PANEL

- C. Austin (Manchester)  
D. Bhatnagar (Oldham)  
I. Biaggioni (Nashville, TN)  
C. E. Brightling (Leicester)  
A. Burt (Newcastle upon Tyne)  
D. Callen (Adelaide, S. Aus.)  
J. D. Cameron (Dandenong, Vic.)  
A. Carter (Leeds)  
J. P. F. Chin-Dusting (Melbourne)  
P. Chowienczyk (London)  
S. Duthie (Aberdeen)  
K. Evans (Stafford)  
A. Ferrante (North Adelaide)  
J. Floras (Toronto)  
G. A. Ford (Newcastle upon Tyne)  
D. Freeman (Glasgow)  
L.-M. Gan (Goteburg)  
G. J. Gibson (Newcastle upon Tyne)  
S. Gough (Birmingham)  
A. Graham (Glasgow)  
G. Grassi (Milan)  
D. J. Green (Nedlands, WA)  
F. R. Green (Oxford)  
M. Grimm (Kogarah, NSW)  
N. Haites (Aberdeen)  
M. Hecker (Goettingen)  
S. Hope (Melbourne)  
J. D. Imig (Augusta, GA)  
E. W. Inscho (Augusta, GA)  
B. Jilma (Vienna)  
W. Koch (Munich)  
L. Kritharides (Sydney)  
D. S. Kumararatne (Cambridge)  
T. Kuo (Hualien)  
P. Little (Melbourne)
- D. Lobo (Nottingham)  
R. A. Malik (Manchester)  
J. Mullins (Edinburgh)  
S. Nagueh (Houston, TX)  
L. Ng (Leicester)  
M. J. O'Leary (Sydney)  
T. Omland (Oslo)  
G. Parati (Milan)  
S. Phillips (Hamilton)  
G. Piccirillo (Rome)  
M. Rademaker (Christchurch, NZ)  
J. Rhodes (Liverpool)  
R. Rush (Adelaide)  
F. C. Schmalstieg, Jr (Galveston)  
T. Shimosawa (Tokyo)  
C. C. Shoulders (London)  
S. S. Smyth (Chapel Hill, NC)  
J. Staessen (Leuven)  
H. Stauss (Berlin)  
I. Striz (Prague)  
S. R. Thomas (Sydney)  
N. C. Thomson (Glasgow)  
V. Thongboonkerd (Bangkok)  
H. Tomiyama (Tokyo)  
J. J. Van Lieshout (Amsterdam)  
M. Verma (Bethesda)  
S. Watts (East Lansing)  
J. Wernerman (Huddinge)  
M. J. West (Chermside, QLD)  
M. J. White (Birmingham)  
J. Wilson (Bankstown, NSW)  
R. Woodman (Perth, WA)  
C. Zhang (Memphis)  
J. Zicha (Prague)



**Published by Portland Press on behalf of the  
Biochemical Society**

© **The Biochemical Society 2006**

**ISSN 0143-5221**

Printed in Great Britain by the Charlesworth Group, Wakefield

## A U T H O R I N D E X

- A**hima, R. S. 143–152  
 Ajamieh, H. 563–573  
 Al-Amri, M. 1–9  
 Alba, J.S. 563–573  
 Alcaraz, A. 227–233  
 Al-Ghafra, A. 337–342  
 Allen, S. J. 175–191  
 Andersen, H. L. 665–671  
 Andersson, B. 329–336  
 Andersson, I. J. 217–225  
 Andre, P. 369–377  
 Ashton, T. 133–141  
 Atuch, N. M. 227–233  
 Azzouz, M. 37–46
- B**acevicius, E. 491–501  
 Bailey, D. M. 133–141  
 Barle, H. 93–99  
 Bartels, N. K. 117–123  
 Baschnegger, H. 207–215  
 Bates, D. O. 575–585  
 Bauer, A. 207–215  
 Baum, O. 587–595  
 Bech, J. N. 491–501  
 Bentzon, J. F. 665–671  
 Bergh, C.-H. 329–336  
 Bergström, G. 217–225  
 Berlanga, J. 563–573  
 Bevan, H. S. 575–585  
 Bianchi, S. M. 293–304  
 Binley, K. 37–46  
 Bohlooly-y, M. 217–225  
 Boisseau, N. 133–141  
 Boon, N. A. 353–360  
 Borén, J. 217–225  
 Börgel, J. 117–123  
 Bouhaddi, M. 369–377  
 Bouter, L. M. 597–604  
 Boyle, J. J. 563–573  
 Brennecke, S. P. 337–342  
 Brown, T. I. 21–35  
 Bruce, C. T. 265  
 Bruegger, D. 207–215  
 Büchner, N. 117–123  
 Burnett, A. L. 153–165  
 Burrell, L. M. 109–116
- C**aidahl, K. 217–225  
 Calafiore, P. 109–116  
 Callera, G. E. 243–253  
 Cappelle, S. 369–377  
 Carducci, C. 459–465  
 Carr, S. J. 101–108  
 Castaño, G. 459–465  
 Castell, L. 133–141  
 Cejka, D. 47–58  
 Chan, P. K. S. 192–204  
 Channon, K. 467–473  
 Chao, M. V. 167–173  
 Chappell, S. 443–458  
 Choukér, A. 207–215  
 Christ, F. 207–215  
 Cibrián, D. 563–573  
 Clarke, K. 467–473  
 Claydon, V. E. 343–352  
 Crosbie, E. J. 543–552  
 Cymerman, A. 683–692
- D**avies, B. 133–141  
 Davison, G. W. 133–141  
 Dawbarn, D. 175–191  
 Dawson, P. 353–360  
 Dekker, J. M. 597–604  
 Delemarre-van de Waal, H. A. 361–368  
 Demetz, F. 207–215  
 Dietz, K. 655–663  
 Di Scala, M. 459–465  
 Ditzler, D. 683–692  
 Dobešová, Z. 235–242  
 Dockrell, D. H. 293–304  
 Donaldson, L. F. 575–585  
 Doorbar, J. 525–541  
 Dorairaj, P. 1–9  
 Doyon, J. 645–654  
 Ducharme, A. 483–499  
 Dunnett, S. B. 73–88
- E**gginton, S. 587–595  
 Emery, S. 59–71  
 Epplen, J. T. 117–123  
 Evangelista, S. 227–233
- F**alk, E. 665–671  
 Felx, M. 645–654  
 Fentum, B. 101–108  
 Fly, A. D. 387–392  
 Franchi, P. 459–465  
 Fretschner, R. 655–663  
 Freyre, F. 563–573  
 Fu, M. 329–336  
 Fujino, N. 125–131  
 Fujita, T. 125–131  
 Fulco, C. S. 683–692  
 Funahashi, T. 267–278
- G**amble, J. 207–215  
 Gan, L.-M. 217–225  
 Garcia Del Barco, D. 563–573  
 Garcia, J. M. 133–141  
 Garcia-Estañ, J. 227–233  
 Garlick, P. J. 93–99  
 Ghosh, S. 563–573  
 Gill, J. M. R. 409–425  
 Glover, J. L. 254–263  
 Gong, M. 315–326  
 Goodlad, R. A. 563–573  
 Grace, F. 133–141  
 Gude, N. M. 337–342  
 Guertin, M.-C. 483–499  
 Guillen, G. 563–573  
 Gustafsson, M. 217–225  
 Guyot, M.-C. 645–654
- H**aider, D. 605–609  
 Hainsworth, R. 343–352  
 Hammarqvist, F. 93–99  
 Handley, O. J. 73–88  
 Harper, S. J. 575–585  
 Harris, R. A. 387–392  
 He, Y. 483–499  
 Heine, R. J. 597–604  
 Henry, R. M. A. 597–604  
 Hiscock, N. 133–141  
 Hoelzl, J. 207–215  
 Holen, I. 279–291  
 Hubner, N. 315–326  
 Hudson, S. J. 575–585
- Huesing, A. 117–123  
 Hui, D. S. C. 192–204  
 Hullin, D. 133–141  
 Hunter, A. J. 575–585
- I**brahim, R. 483–499  
 Ijzerman, R. G. 361–368  
 Ino, H. 125–131  
 Isler, M. 645–654
- J**ackson, M. B. 143–152  
 Jansson, P.-A. 329–336  
 Jartti, L. 475–482  
 Järvisalo, M. J. 475–482  
 Jendeková, L. 235–242  
 Jerums, G. 109–116  
 Jin, L. 153–165  
 Johansson, M. E. 217–225  
 Jordan, J. 343–352
- K**aneda, T. 125–131  
 Khatib, A.-M. 645–654  
 Kihara, S. 267–278  
 Kim, M. J.-T. 563–573  
 King, R. G. 337–342  
 Kitchener, H. C. 543–552  
 Klaude, M. 93–99  
 Klintland, N. 217–225  
 Kojšová, S. 235–242  
 Konno, T. 125–131  
 Kristiansen, S. B. 665–671  
 Krugluger, W. 605–609  
 Krzyzanowska, K. 605–609  
 Kuneš, J. 235–242
- L**acy, P. 101–108  
 Lammi, E. 683–692  
 Lavoie, J. 483–499  
 Leclerc, S. 645–654  
 Lee, F. S. 167–173  
 Lehtimäki, T. 475–482  
 Lemberg, A. 459–465  
 León, O. S. 563–573  
 Levick, J. R. 553–561  
 Lewis, S. F. 683–692  
 Libby, P. 267–278

- Lopez-Saura, P. 563–573  
 Losert, D. 47–58  
 Louisy, F. 369–377  
 Lowe, G. D. O. 327–328  
 Lucangioli, S. 459–465  
 Ludlam, C. A. 353–360
- M**  
 Mabuchi, H. 125–131  
 Mabuchi, T. 125–131  
 MacIsaac, R. J. 109–116  
 MacMillan, P. P. 575–585  
 Madsen, P. L. 467–473  
 Malkova, D. 409–425  
 Manjaly, J. G. 575–585  
 Marchbank, T. 563–573  
 Marniemi, J. 475–482  
 Martignoni, A. 207–215  
 Masuta, E. 125–131  
 Matsuzawa, Y. 267–278  
 Mazarakis, N. D. 37–46  
 McArdle, N. 89–91  
 McDermid, J. M. 503–524  
 McEneny, J. 133–141  
 McIntosh, R. S. 11–19  
 Medow, M. S. 254–263  
 Mellor, R. H. 553–561  
 Merani, S. 611–625  
 Mesquida, M. 459–465  
 Mikehiev, A. 369–377  
 Mittermayer, F. 605–609  
 Mobini, R. 329–336  
 Modi, S. 553–561  
 Moldovan, F. 645–654  
 Montezano, A. C. I.  
 243–253  
 Moreau, A. 645–654  
 Morgan, L. 443–458  
 Morgan, R. M. 133–141  
 Mortimer, P. S. 553–561  
 Mourot, L. 369–377  
 Mügge, A. 117–123  
 Muza, S. R. 683–692
- N**  
 Naji, J. J. 73–88  
 Nath, A. 393–407  
 Navarro, E. G. 227–233  
 Neubauer, S. 467–473
- Newby, D. E. 353–360  
 Nijpels, G. 597–604  
 Norcliffe, L. J. 343–352  
 Nygren, A. 673–681  
 Nyström, T. 673–681
- O**  
 O'Brien, D. 101–108  
 Okamoto, Y. 267–278  
 Ortiz, M. C. 227–233  
 O'Valle, F. 227–233
- P**  
 Padilla, J. 387–392  
 Paul, S. K. 101–108  
 Pecháňová, O. 235–242  
 Pedersen, E. B. 491–501  
 Pedersen, H. B. 491–501  
 Perez-Perez, G. I. 305–314  
 Peter, J. 207–215  
 Peters, A. M. 553–561  
 Playford, R. J. 563–573  
 Pleass, R. J. 11–19  
 Polak, B. P. 597–604  
 Pollock, D. M. 205–206  
 Portal-Celhay, C. 305–314  
 Prentice, A. M. 503–524  
 Pries, A. R. 587–595  
 Puls, R. L. 59–71
- Q**  
 Qiu, Y. 575–585
- R**  
 Racine, N. 483–499  
 Rahman, R. 605–609  
 Raitakari, O. T. 475–482  
 Rajagopal, R. 167–173  
 Ralph, G. S. 37–46  
 Read, M. 575–585  
 Regnard, J. 369–377  
 Renshaw, S. A. 293–304  
 Reutershan, J. 655–663  
 Rink, L. D. 387–392  
 Robinson, S. D. 353–360  
 Robinson, T. G. 101–108  
 Roghanian, A. 21–35  
 Rönnemaa, T. 475–482  
 Rooyackers, O. 93–99  
 Rosser, A. E. 73–88  
 Rouleau, J. L. 483–499
- Rumbach, L. 369–377  
 Rumbaugh, J. A. 393–407  
 Rump, L. C. 117–123
- S**  
 Sabroe, I. 293–304  
 Sakata, K. 125–131  
 Sallenave, J.-M. 21–35  
 Sanner, B. M. 117–123  
 Santamaria, P. 627–639  
 Scharin Täng, M. 329–336  
 Schernthaner, G. 605–609  
 Scheuermann Freestone, M.  
 467–473  
 Schiffrin, E. L. 483–499  
 Schmitt, A. 655–663  
 Schmoelz, M. 207–215  
 Schroeder, C. 343–352  
 Schroepfer, S. 207–215  
 Schulz, T. 117–123  
 Seko, Y. 379–386  
 Serné, E. H. 361–368  
 Shapiro, A. M. J. 611–625  
 Shi, J. 11–19  
 Shimizu, M. 125–131  
 Shipman, C. M. 279–291  
 Shnawa, N. 605–609  
 Silva-Azevedo, L. D. A.  
 587–595  
 Simonsen, U. 665–671  
 Sjöholm, Å. 673–681  
 Smith, J. 1–9  
 Sniderman, A. 1–9  
 Solling, K. 491–501  
 Sookoian, S. 459–465  
 Soothill, P. W. 575–585  
 Srivastava, P. M. 109–116  
 Stanton, A. W. B. 553–561  
 Stehouwer, C. D. A.  
 361–368, 597–604  
 Stewart, J. M. 254–263  
 Stolk, R. P. 597–604  
 Svensson, W. E. 553–561
- T**  
 Tamm, I. 427–442  
 Tang, J. W. 192–204  
 Thiel, M. 207–215  
 Thim, T. 665–671
- Thomas, M. C. 109–116  
 Thomas, P. S. 265  
 Tostes, R. C. 243–253  
 Touyz, R. M. 243–253,  
 483–499  
 Treacher, D. F. 641–643  
 Tripodi, V. 459–465  
 Turcotte, R. E. 645–654
- U**  
 Uchiyama, K. 125–131  
 Unertl, K. 655–663
- V**  
 van Hecke, M. V. 597–604  
 van Weissenbruch, M. M.  
 361–368  
 Vargas, F. 227–233  
 Viikari, J. S. A. 475–482  
 Voordouw, J. J. 361–368  
 Vuillier, F. 369–377
- W**  
 Waagstein, F. 329–336  
 Wacheck, V. 47–58  
 Wallace, J. P. 387–392  
 Wang, T. 393–407  
 Wassermann, K. 665–671  
 Weichert, A. 587–595  
 Wernerman, J. 93–99  
 Westman, B. 93–99  
 White, M. 483–499  
 Whittom, L. 483–499  
 Whyte, M. K. B. 293–304  
 Wickman, A. 217–225  
 Williams, B. 101–108  
 Williams, J. L. 587–595  
 Williams, S. E. 21–35  
 Wolf, J.-P. 369–377  
 Wong, L.-F. 37–46
- Y**  
 Yang, Y. 627–639  
 Yao, G. 483–499  
 Yogi, A. 243–253  
 Young, I. S. 133–141  
 Yudkin, J. S. 361–368
- Z**  
 Zakrzewicz, A. 587–595  
 Zicha, J. 235–242

## S U B J E C T I N D E X

- A**  
**Acetazolamide**  
 acute mountain sickness, metabolic acidosis 683–692  
**N-acetylcysteine**  
 hypertension, reactive oxygen species 235–242  
**Acute mountain exercise**  
 acetazolamide, metabolic acidosis 683–692  
**Acute myocarditis**  
 angiotensin II, coxsackievirus B3 379–386  
**Acute respiratory distress syndrome (ARDS)**  
 alveolar recruitment, prone positioning 641–643, 655–663  
**Adipocyte**  
 life cycle, obesity 1–9  
**Adipocyte-derived hormone**  
 neuroendocrine, obesity 143–152  
**Adipocytokine**  
 gestational diabetes mellitus, visfatin 605–609  
**Adiponectin**  
 metabolic syndrome, visceral obesity 267–278  
 $\beta_1$ -Adrenoceptor  
 cardiovascular response, obstructive sleep apnoea 89–91, 117–123  
**Adrenomedullin**  
 fetal membrane, parturition 337–342  
**Aerobic exercise**  
 free radical, oxidative stress 133–141  
**Alveolar recruitment**  
 acute respiratory distress syndrome (ARDS), prone positioning 641–643, 655–663  
**Anaemia**  
 diastolic dysfunction, Type II diabetes 109–116  
**Angiogenesis**  
 capillary splitting, sprouting 587–595  
**Angiotensin II**  
 acute myocarditis, coxsackievirus B3 379–386  
 postural tachycardia syndrome (POTS), vasoconstriction 255–263  
**Angiotensin-converting enzyme (ACE)**  
 diuretic, hypertension 227–233  
**Animal model**  
 autoimmunity, Type I diabetes 627–639  
**Antibody-based therapy**  
 malaria, *Plasmodium* antigen 11–19  
**Antisense oligonucleotide (As ODN)**  
 cancer, malignant disease 427–442  
**Apoptosis**  
 granulocyte, lung disease 293–304  
**Asthma**  
 depression, neurotrophin 175–191  
 inflammation, tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ) 265  
**Autoimmunity**  
 animal model, Type I diabetes 627–639  
**Autonomic dysfunction**  
 chronic kidney disease, glomerular filtration 101–108  
**B**  
**Bile acid**  
 intrahepatic cholestasis, pregnancy 459–465  
**Blood pressure**  
 hypertension, molecular basis 315–326  
**Bone turnover**  
 metastatic bone disease, osteoprotegerin 279–291  
**Breast cancer**  
 lymph flow, quantitative lymphoscintigraphy 553–561  
**C**  
**Cancer**  
 antisense oligonucleotide (As ODN), malignant disease 427–442  
**Candidate gene**  
 genome-wide screening, pre-eclampsia 443–458  
**Capillary recruitment**  
 insulin resistance, tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ) 361–368  
**Capillary splitting**  
 angiogenesis, sprouting 587–595  
**Cardiovascular disease**  
 fitness, physical activity 409–425  
**Cardiovascular response**  
 $\beta_1$ -adrenoceptor, obstructive sleep apnoea 89–91, 117–123  
**Central nervous system**  
 neurotrophin, peripheral nervous system 175–191  
**Cervical cancer**  
 human papillomavirus (HPV), Pap smear 543–552  
 infection, human papillomavirus (HPV) 525–541  
**Cholecystitis**  
 inflammation, liver protein synthesis 93–99  
**Chronic heart failure**  
 myocardial metabolism, sympathetic nervous system 329–336  
**Chronic kidney disease**  
 autonomic dysfunction, glomerular filtration 101–108  
**Colonization**  
*Helicobacter pylori*, immune response 305–314  
**Coronary heart disease**  
 endothelial function, tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ) 327–328, 353–360  
**Coronavirus**  
 severe acute respiratory syndrome (SARS), viral transmission 192–204  
**Coxsackievirus B3**  
 acute myocarditis, angiotensin II 379–386

- Dementia**  
inflammation, neuropathogenesis  
393–407
- Depression**  
asthma, neurotrophin 175–191
- Diastolic dysfunction**  
anaemia, Type II diabetes 109–116
- Diuretic**  
angiotensin-converting enzyme  
(ACE), hypertension 227–233
- L-dopa**  
Parkinson's disease, peripheral  
venous tone 369–377
- Elafin**  
immune response, secretory  
leucocyte protease inhibitor  
(SLPI) 21–35
- Endothelial dysfunction**  
growth hormone, transgenic mouse  
217–225  
inflammation, Type II diabetes  
673–681  
myocardial infarction, tumour  
necrosis factor- $\alpha$  (TNF- $\alpha$ )  
673–681
- Endothelial function**  
coronary heart disease, tumour  
necrosis factor- $\alpha$  (TNF- $\alpha$ )  
327–328, 353–360  
hyperaemia, vasodilation 387–392  
microvascular dysfunction,  
retina 597–604
- Endothelin**  
hypertension, oxidative stress  
205–206, 243–253  
matrix metalloproteinase (MMP),  
osteosarcoma 645–654
- Erectile tissue**  
RhoA/Rho-kinase, smooth muscle  
153–165
- Exercise**  
high altitude, microvascular  
parameter 207–215
- Fetal membrane**  
adrenomedullin, parturition  
337–342
- Fitness**  
cardiovascular disease, physical  
activity 409–425
- Flow-mediated dilation**  
haemoglobin, Type II diabetes  
467–473  
intima-media thickness,  
microvascular dysfunction  
597–604
- low-fat meal, sympathetic tone  
475–482
- Free radical**  
aerobic exercise, oxidative stress  
133–141
- Gene silencing**  
RNA interference (RNAi), short  
interfering RNA (siRNA)  
47–58
- Gene therapy**  
Huntington's disease,  
neurodegenerative disease 73–88  
neurodegenerative disease,  
lentiviral vector 37–46
- Genome-wide screening**  
candidate gene, pre-eclampsia  
443–458
- Gestational diabetes mellitus**  
adipocytokine, visfatin 605–609
- Glomerular filtration**  
autonomic dysfunction, chronic  
kidney disease 101–108
- Granulocyte**  
apoptosis, lung disease 293–304
- Growth hormone**  
endothelial dysfunction, transgenic  
mouse 217–225
- Growth-hormone-releasing peptide  
(GHRP)**  
ischaemia/reperfusion, multiple  
organ failure 563–573
- Haemoglobin**  
flow-mediated dilation, Type II  
diabetes 467–473
- Heart failure**  
inflammation, oxidative stress  
483–489
- Helicobacter pylori***  
colonization, immune response  
305–314
- High altitude**  
exercise, microvascular parameter  
207–215
- HIV**  
immune response, vaccination  
59–71  
iron, tuberculosis 503–524
- Human papillomavirus (HPV)**  
cervical cancer, infection  
525–541  
screening, vaccination 543–552
- Huntington's disease**  
gene therapy, neurodegenerative  
disease 73–88
- Hyperaemia**  
endothelial function, vasodilation  
387–392
- Hypertension**  
N-acetylcysteine, reactive oxygen  
species 235–242  
angiotensin-converting enzyme  
(ACE), diuretic 227–233  
blood pressure, molecular basis  
315–326  
endothelin, oxidative stress  
205–206, 243–253  
mitochondria, NADPH oxidase  
243–253
- Hypertrophic cardiomyopathy**  
myosin-binding protein, sudden  
death 125–131
- Immune response**  
colonization, *Helicobacter pylori*  
305–314  
elafin, secretory leucocyte  
protease inhibitor (SLPI)  
21–35  
HIV, vaccination 59–71
- Infection**  
cervical cancer, human  
papillomavirus (HPV) 525–541  
iron, pathogen 503–524
- Inflammation**  
asthma, tumour necrosis factor- $\alpha$   
(TNF- $\alpha$ ) 265  
cholecystitis, liver protein synthesis  
93–99  
dementia, neuropathogenesis  
393–407  
heart failure, oxidative stress  
483–489  
HIV, virus
- Insulin resistance**  
capillary recruitment, tumour  
necrosis factor- $\alpha$  (TNF- $\alpha$ )  
361–368  
fitness, obesity 409–425
- Intima-media thickness**  
flow-mediated dilation,  
microvascular dysfunction  
597–604
- Intrahepatic cholestasis**  
bile acid, pregnancy 459–465
- Iron**  
infection, pathogen 503–524
- Ischaemia/reperfusion**  
growth-hormone-releasing peptide  
(GHRP), multiple organ failure  
563–573

- metabolic syndrome, myocardial infarction 665–671
- Islet transplantation  
pancreatic  $\beta$ -cell, Type I diabetes 611–625
- L**entiviral vector  
gene therapy, neurodegenerative disease 37–46
- Life cycle  
adipocyte, obesity 1–9
- Liver protein synthesis  
cholecystitis, inflammation 93–99
- Low-fat meal  
flow-mediated dilation, sympathetic tone 475–482
- Lung disease  
apoptosis, granulocyte 293–304
- Lymph flow  
breast cancer, quantitative lymphoscintigraphy 553–561
- M**alaria  
antibody-based therapy, *Plasmodium* antigen 11–19
- Malignant disease  
antisense oligonucleotide (As ODN), cancer 427–442
- Matrix metalloproteinase (MMP)  
endothelin, osteosarcoma 645–654
- Metabolic acidosis  
acetazolamide, acute mountain sickness 683–692
- Metabolic syndrome  
adiponectin, visceral obesity 267–278  
ischaemia/reperfusion, myocardial infarction 665–671
- Metastatic bone disease  
bone turnover, osteoprotegerin 279–291
- Microvascular dysfunction  
flow-mediated dilation, intima-media thickness 597–604
- Microvascular parameter  
exercise, high altitude 207–215
- Molecular basis  
blood pressure, hypertension 315–326
- Multiple organ failure  
growth-hormone-releasing peptide (GHRP), ischaemia/reperfusion 563–573
- Myocardial infarction  
endothelial dysfunction, tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ) 673–681
- ischaemia/reperfusion, metabolic syndrome 665–671
- Myocardial metabolism  
chronic heart failure, sympathetic nervous system 329–336
- Myosin-binding protein  
hypertrophic cardiomyopathy, sudden death 125–131
- N**atriuretic peptide  
pulsatile secretion, renal failure 491–501
- Neurodegenerative disease  
gene therapy, lentiviral vector 37–46  
Huntington's disease, gene therapy 73–88  
neurotrophin, receptor activation 167–173
- Neuroendocrine  
adipocyte-derived hormone, obesity 143–152
- Neuropathogenesis  
dementia, inflammation 393–407
- Neurotrophin  
asthma, depression 175–191  
neurodegenerative disease, receptor activation 167–173
- O**besity  
adipocyte, life cycle 1–9  
neuroendocrine, adipocyte-derived hormone 143–152
- Obstructive sleep apnoea  
 $\beta_1$ -adrenoceptor, cardiovascular response 89–91, 117–123
- Orthostatic tolerance  
posturally related syncope, water 343–352
- Osteoprotegerin  
bone turnover, metastatic bone disease 279–291
- Osteosarcoma  
endothelin, matrix metalloproteinase (MMP) 645–654
- Oxidative stress  
aerobic exercise, free radical 133–141  
endothelin, hypertension 205–206, 243–253  
heart failure, inflammation 483–489
- P**ancreatic  $\beta$ -cell  
islet transplantation, Type I diabetes 611–625
- Parkinson's disease  
L-dopa, peripheral venous tone 369–377
- Parturition  
adrenomedullin, fetal membrane 337–342
- Pathogen  
infection, iron 503–524
- Peripheral venous tone  
L-dopa, Parkinson's disease 369–377
- Physical activity  
cardiovascular disease, fitness 409–425
- Plasmodium* antigen  
antibody-based therapy, malaria 11–19
- Postural tachycardia syndrome (POTS)  
angiotensin II, vasoconstriction 255–263
- Posturally related syncope  
orthostatic tolerance, water 343–352
- Pre-eclampsia  
candidate gene, genome-wide screening 443–458  
splice variant, vascular endothelial growth factor (VEGF) 575–585
- Pregnancy  
bile acid, intrahepatic cholestasis 459–465
- Prone positioning  
acute respiratory distress syndrome (ARDS), alveolar recruitment 641–643, 655–663
- Pulsatile secretion  
natriuretic peptide, renal failure 491–501
- Q**uantitative lymphoscintigraphy  
breast cancer, lymph flow 553–561
- R**eactive oxygen species  
N-acetylcysteine, hypertension 235–242
- Receptor activation  
neurodegenerative disease, neurotrophin 167–173
- Renal failure  
natriuretic peptide, pulsatile secretion 491–501
- RhoA/Rho-kinase  
erectile tissue, smooth muscle 153–165
- RNA interference (RNAi)  
gene silencing, short interfering RNA (siRNA) 47–58



**S**creening

- human papillomavirus (HPV),  
vaccination 543–552
- Secretory leucocyte protease  
inhibitor (SLPI)  
elafin, immune response 21–35
- Severe acute respiratory syndrome  
(SARS)  
coronavirus, viral transmission  
192–204
- Short interfering RNA (siRNA)  
gene silencing, RNA interference  
(RNAi) 47–58
- Smooth muscle  
erectile tissue, RhoA/Rho-kinase  
153–165
- Splice variant  
pre-eclampsia, vascular endothelial  
growth factor (VEGF)  
575–585
- Sprouting  
angiogenesis, capillary splitting  
587–595
- Sudden death  
hypertrophic cardiomyopathy,  
myosin-binding protein  
125–131

## Sympathetic nervous system

- chronic heart failure, myocardial  
metabolism 329–336
- Sympathetic tone  
flow-mediated dilation, low-fat meal  
475–482

**T**ransgenic mouse

- endothelial dysfunction, growth  
hormone 217–225
- Tumour necrosis factor- $\alpha$  (TNF- $\alpha$ )  
asthma, inflammation 265
- capillary recruitment, insulin  
resistance 361–368
- coronary heart disease, endothelial  
function 327–328, 353–360
- endothelial dysfunction, myocardial  
infarction 673–681

## Type I diabetes

- animal model, autoimmunity  
627–639
- islet transplantation, pancreatic  
 $\beta$ -cell 611–625

## Type II diabetes

- anaemia, diastolic dysfunction  
109–116
- flow-mediated dilation,  
haemoglobin 467–473

**V**accination

- HIV, immune response 59–71
- human papillomavirus (HPV),  
screening 543–552
- Vascular endothelial growth factor  
(VEGF)  
pre-eclampsia, splice variant  
575–585
- Vasoconstriction  
angiotensin II, postural tachycardia  
syndrome (POTS) 255–263
- Vasodilation  
endothelial function, hyperaemia  
387–392
- Viral transmission coronavirus  
severe acute respiratory syndrome  
(SARS) 192–204
- Visceral obesity  
adiponectin, metabolic syndrome  
267–278
- Visfatin  
adipocytokine, gestational diabetes  
mellitus 605–609

**W**ater

- orthostatic tolerance, posturally  
related syncope 343–352